Quantifizierung des Mistellektins I aus Mistelextrakt-Fertigarzneimitteln

Zusammenfassung

Die Anwendung der Mistel (Viscum album L.) in der komplementären Krebstherapie ist ein etabliertes Verfahren mit großer Akzeptanz bei den Patienten. Zurzeit gibt es in Deutschland fünf Mistelpräparate, die sich im Herstellungsprozess und in der Art des Wirtsbaums unterscheiden. Ziel dieser Arbeit war die Quantifizierung eines der vermutlichen Hauptwirkungskomponenten Mistellektin I mit zwei verschiedenen Varianten eines ELISA (Enzyme-linked Immunosorbent Assay). Es wurden sowohl die A-Kette als auch das Hololectin (A-B-Kette) bestimmt. Deutliche Unterschiede im Mistellektingehalt zwischen den einzelnen Fertigarzneimitteln konnten je nach herstellerspezifischem Fertigungsprozess und Art des Wirtsbaums ermittelt werden.

Summary

Quantification of the mistletoe lectin I from pharmaceutical products

The use of mistletoe (Viscum album L.) is well established in the complementary therapy to treat cancer connected with high acceptance among the patients. Today, there are five mistletoe preparations available in Germany which differ in the manufacturing process and in the type of host tree. The aim of this work was to quantify one of the presumed main active components the mistletoe lectin I by two different ELISA (enzyme-linked immunosorbent assay). Either the a-chain or the hololectin (a-b-chain) were determined. Significant differences in the concentration of mistletoe lectin could be detected depending on the producer and on the type of host tree.

Schlüsselwörter

Viscum album L. - Misteltherapie - Mistellektin - Hololectin - ELISA

Keywords

Viscum album L. - mistletoe therapy - mistletoe lectin concentration - hololectin - ELISA

• Literatur

• 1 Robert Koch Institute, ed. Health in Germany. Federal Health Reporting Joint Service by RKI and Destatis 2015 http://www.rki.de/EN/Content/Health_Monitoring/Health_Reporting/HealthInGermany/Health-in-Germany_short_summary.pdf?__blob=publicationFile
• 2 Bausell RB, Lee WL, Berman BM. . Demographic and health-related correlates to visits to complementary and alternative medical providers. Med Care 2001; 39: 190-196
• 3 Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9: 142-157
• 4 Lange-Lindberg AM, Velasco-Garrido M, Busse R. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. In: Schriftenreihe Health Technology Assessment in der Bundesrepublik Deutschland. Köln: DIMDI; 2006
• 5 Horneber MA, Bueschel G, Huber R. et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; (02) Cd003297
• 6 Kienle GS, Glockmann A, Schink M. et al. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009; 28: 79
• 7 Bopp A, Kienle GS. Gesellschaft Anthroposophischer Ärzte in Deutschland. Informationen zur Misteltherapie bei Krebs http://www.misteltherapie.de
• 8 Kienle GS, Kiene H. Die Mistel in der Onkologie – Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer; 2003
• 9 Fachinformationsverzeichnis. Rote Liste: Rote Liste Service GmbH; 2016
• 10 Van Damme EJM, Hao Q, Chen Y. et al. Ribosome-inactivating proteins: a family of plant proteins that do more than inactivate ribosomes. Crit Rev Plant Sci 2001; 20: 395-465
• 11 de Virgilio M, Lombardi A, Caliandro R. et al. Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins (Basel) 2010; 2: 2699-2737
• 12 Hajto T, Hostanska K, Fischer J. et al. Immunomodulatory effects of Viscum album agglutinin-I on natural immunity. Anti-Cancer Drugs 1997; 8 Suppl. 1 S43-S46
• 13 Fischer S. Stimulation der Immunabwehr durch Mistelinhaltsstoffe – In-vitro-Versuche zur T-Zellreaktivität. Carstens Stiftung 1996
• 14 AbnobaGmbH. ABNOBA Anwendungsempfehlungen 2008
• 15 Jaeggy C, Musielski H, Urech K. et al. Quantitative determination of lectins in mistletoe preparations. Arzneimittelforsch 1995; 45: 905-909
• 16 Manojlovic V, Winkler K, Bunjes V. et al. Membrane interactions of ternary phospholipid/cholesterol bilayers and encapsulation efficiencies of a RIP II protein. Colloids Surf B 2008; 64: 284-296
• 17 Mulsow K, Enzlein T, Delebinski C. et al. Impact of mistletoe triterpene acids on the uptake of mistletoe lectin by cultured tumor cells. PLoS One 2016; 11: e0153825
• 18 Delebinski CI, Twardziok M, Kleinsimon S. et al. A natural combination extract of Viscum album L. containing both triterpene acids and lectins is highly effective against AML in vivo. PLoS One 2015; 10: e0133892
• 19 Mulsow K. Zellbiologische und analytische Untersuchungen zu Lektinen und Triterpenen der Mistel (Viscum album L.) [Dissertation]. Berlin: Freie Universität; 2016
• 20 Ziska P, Franz H. Studies on the interaction of the mistletoe lectin I with carbohydrates. Experientia 1981; 37: 219
• 21 Franz H. Mistletoe lectins and their A and B chains. Oncology 1986; 43 Suppl. 1 23-34
• 22 Mengs U, Goethel D, Leng-Peschlow E. et al. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 2002; 22: 1399-1407
• 23 Muething J, Meisen I, Bulau P. et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Acα2-6Galβ1-4GlcNAc residues. Biochemistry 2004; 43: 2996-3007
• 24 Vervecken W, Kleff S, Pfüller U, Büssing A. Induction of apoptosis by mistletoe lectin I and its subunits. No evidence for cytotoxic effects caused by isolated A- and B-chains. Int J Biochem Cell Biol 2000; 32: 317-326
• 25 Pfüller U, Pfüller K. Self-cleavage of mistletoe lectin I into the A and the B subunit by thiol-disulfide exchange reaction. Phytomedicine 2007; 14 Suppl. 2 45